Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 02, 2023

BUY
$6.49 - $13.36 $4.63 Million - $9.54 Million
714,037 New
714,037 $7.24 Million
Q1 2023

Jun 13, 2024

BUY
$3.78 - $10.38 $362,985 - $996,770
96,028 New
96,028 $932,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $70.2M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.